secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entera Bio Ltd. (ENTXW)
CIK:        0001638097
Form:       8-K
Filed at:   2024-08-09T23:59:59+00:00
Accession:  0001178913-24-002520
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entera Bio Q2 2024 net loss $2.1M; cash runway into Q3 2025; EB613 milestone expected
--------------------------------------------------------------------------------

- Net loss of $2.1M ($0.06 per share) vs $2.3M ($0.08) in Q2 2023; cash $9.1M at June 30, 2024.
- R&D expenses $1.1M (down $0.1M YoY); G&A flat at $1.1M; operating expenses $2.2M.
- EB613 (oral PTH) Phase 2 data published in JBMR; FDA SABRE endpoint ruling expected ~5 months.
- EB612 hypoparathyroidism Phase 1 data at ENDO 2024; potential move to Phase 2 soon.
- Collaboration with OPKO on oral GLP-2 (short bowel) and GLP-1/glucagon (obesity) ongoing; PK data due H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638097/000117891324002520/0001178913-24-002520-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638097/000117891324002520/zk2431821.htm
  HTML page:      https://secwatch.observer/filing/0001178913-24-002520

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer